Abstract Branchio-oto-renal (BOR) syndrome is an autosomal dominant disorder characterized by branchial arch anomalies, hearing loss and renal dysmorphology. Although haploinsufficiency of EYA1 and SIX1 are known to cause BOR, copy number variation analysis has only been performed on a limited number of BOR patients. In this study, we used high-resolution array-based comparative genomic hybridization on 32 BOR probands negative for coding-sequence and splice-site mutations in known BOR-causing genes to identify potential disease-causing genomic rearrangements. Of the [1,000 rare and novel copy number variants we identified, four were heterozygous deletions of EYA1 and several downstream genes that had nearly identical breakpoints associated with retroviral sequence blocks, suggesting that non-allelic homologous recombination seeded by this recombination hotspot is important in the pathogenesis of BOR. A different heterozygous deletion removing the last exon of EYA1 was identified in an additional proband. Thus, in total five probands (14 %) had deletions of all or part of EYA1. Using a novel disease-gene prioritization strategy that includes network analysis of genes associated with other deletions suggests that SHARPIN (Sipl1), FGF3 and the HOXA gene cluster may contribute to the pathogenesis of BOR.
Introduction
Branchio-otic (BO) syndrome is an autosomal dominant disorder characterized by branchial cleft cysts, auricular or external auditory canal abnormalities, preauricular pits and hearing loss. Branchio-oto-renal (BOR) syndrome is diagnosed when BO is accompanied by malformations of the kidney or urinary tract, which range from mild hypoplasia to complete absence of one or both kidneys (Fraser et al. 1978; Matsunaga et al. 2007; Ruf et al. 2004) . Multiple studies have shown that BOR is incompletely penetrant with variable expressivity, consistent with wide phenotypic variability between and within families. The most common manifestation is hearing loss, which can be conductive, sensorineural, or mixed (Hone and Smith 2001) . Some studies estimate that BO/BOR has a prevalence of 2 % amongst profoundly deaf children (Fraser et al. 1980) . BOR is genetically heterogeneous, although mutations in EYA1 are most commonly identified and segregate with the BOR phenotype in about 40 % of families (Abdelhak et al. 1997a, b; Chang et al. 2004; Krug et al. 2011; Matsunaga et al. 2007; Orten et al. 2008) . Causative variants include point mutations as well as large and small deletions (Abdelhak et al. 1997b; Ni et al. 1994; Vincent et al. 1997) . EYA1 encodes a transcriptional regulator (Abdelhak et al. 1997b ) and mice heterozygous for the targeted deletion of this gene have renal abnormalities and a conductive hearing loss similar to the human phenotype. Eya1 homozygous null mice lack ears and kidneys (Xu et al. 1999b) .
Mutations in both SIX1 and SIX5 are also associated with BOR syndrome. SIX1, the human homolog of Drosophila sine oculis gene, encodes a DNA binding protein that associates with EYA1 (Ruf et al. 2004) . Most mutations identified in SIX1 are missense mutations but small deletions have also been reported in patients with BOR syndrome (Kochhar et al. 2008; Ruf et al. 2003 Ruf et al. , 2004 Sanggaard et al. 2007 ). The role of SIX5 in BOR is less clear. Although a few missense mutations in SIX5 have been reported in patients with BOR syndrome (Hoskins et al. 2007; Krug et al. 2011; Ruf et al. 2004) , the role of SIX5 variants in the pathophysiology of BOR has been questioned (Krug et al. 2011) .
The purpose of this study was to assess the role of copy number variation in the BOR phenotype by performing high-resolution array-based comparative genomic hybridization (aCGH) on a cohort of 32 BOR probands negative for coding-sequence and splice-site mutations in the known BOR-causing genes. We identified a recombination hotspot that is responsible for deletion of the EYA1 locus (in addition to several other genes) in four unrelated probands, as well as a second deletion that removes a portion of EYA1 in a fifth proband, further substantiating involvement of this locus in BOR. In addition, using a novel disease-gene prioritization strategy that includes pathway analysis of genes deleted in the remaining probands, we implicate SHARPIN (Sipl1), FGF3, and the HOXA gene cluster as candidate genes that may contribute to the BOR syndrome phenotype.
Materials and methods

Samples selection for array-based CGH
Patients were diagnosed with BOR syndrome based on their clinical phenotype Chen et al. 1995) . Genomic DNA was extracted from the peripheral blood in patients providing informed consent. The isolated genomic DNA was quantified and assessed for quality using a NanoDrop spectrophotometer (Thermo Scientific; Wilmington, DE) and agarose gel electrophoresis. The coding regions and splice sites in EYA1, SIX1, and SIX5 were analyzed by Sanger sequencing. Patients negative for this mutation analysis were eligible for this study. All procedures were approved by the University of Iowa human research internal review board (IRB).
Array-based CGH and CNV detection and interpretation 35 patients were included in this aCGH study but only 32 passed all quality control parameters (see ''Supplementary Material'') . Labeling of the patient samples and a normal male reference was performed using Cy3-and Cy5-labeled random nonamers (TriLink Biotechnologies; San Diego, CA), respectively. The labeled DNAs were hybridized to a NimbleGen human CGH 2.1 million feature whole-genome tiled microarray (v2.0D), and the arrays were processed according to manufacturer's instructions. Microarrays underwent stripping and reuse as described previously (Bassuk et al. 2013 ) and the reuse strategy was further validated (Supplementary Material-Array Reuse Protocol and Noninferiority Testing and Fig. S1 ). The DEVA software tool (version 1.0; Roche NimbleGen) was used for feature extraction, calculation of log 2 ratio values, and segmentation using the segMNT algorithm. Additional CNV calling algorithms and data interpretation were performed using the Nexus Copy Number Discovery Edition software tool (version 5.1, BioDiscovery; El Segundo, CA) and the FASST2 and RANK algorithms supplied with the Nexus software suite. All array data were quality controlled using the experimental metrics calculated by DEVA and Nexus Copy Number (Supplementary Material-Quality Control Analysis of Microarray Data). Array data not meeting quality control thresholds were excluded from further analysis.
CNV pathogenicity determination
CNVs were called with three algorithms (SegMNT, FASST2 and RANK) using permissive settings (Supplementary Material-Copy Number Variation Calling Algorithms and Software) and those regions that exhibited consistent copy number variation across all three algorithms comprised our final CNVR set. This call set met previously determined biologic criteria that included the appropriate ratio of deleted vs. duplicated sequence content, exon/intron/intergenic content, and novel vs. polymorphic regions (Supplementary Material-Biological Assessment of Different Calling Algorithms). All CNVRs were compared against clinically relevant databases and published CNV datasets to determine likely pathogenicity. Data sources included the Database of Genomic Variants (DGV; http://projects.tcag.ca/variation/), the Wellcome Trust Sanger Institute's DECIPHER database (http:// decipher.sanger.ac.uk/), the database curated by the International Standards for Cytogenetic Arrays (ISCA) consortium (https://www.iscaconsortium.org/), our internal clinical array CGH database, and the CNV datasets published by Conrad and Cooper and colleagues [(2010, 2011) (Cooper et al. 2011) ], for CNVs that overlapped the novel deletion interval. Potential overlapping CNVs were excluded if they were known copy number polymorphisms. The region of ''moderate overlap'' was chosen by selecting the interval that contained not only the most overlapping segments of CNVs but an extended region that included the next most overlapping segments on either side (see Supplementary Material-Gene Prioritization within Novel CNVRs and Figure S5 for example). Genes present in the region of moderate overlap were ranked based on the relative overlap of other clinically relevant CNVs. The second method of prioritization was predicted haploinsufficiency. Genes within novel deletion intervals were ranked according to their haploinsufficiency score (Huang et al. 2010) . The third method involved creating and examining protein-protein interaction (PPI) networks. To guide this analysis, we used the published C. elegans interactome (Li et al. 2004 ) in relation to the orthologous human genes to create a hypothetical human EYA1 interactome. Three tiers of potential human EYA1 interacting partners were created (Table S7 ; ''good candidates'' = yellow, ''possible candidates'' = orange, and ''poor candidates'' = red) by determining whether human, mouse, or Xenopus orthologs existed. Peptide BLAST scores were cataloged for each organism, with proteins classified as ''good'' candidates if they had blast hits/ known orthologs in all three vertebrate model organisms. Exceptions were made if orthologs were not present in all three model organisms, but expression data placed the partners together. ''Possible'' candidates had known orthologs in either 1 of 3 or 2 of 3 of the model organisms.
Occasionally, all three model organisms had orthologs but the protein was unlikely to be involved because of its function (for example afd-1, which has been associated with a different disease process unlikely to be related to BOR). In these cases, BLAST scores were included for future potential testing. ''Poor'' candidates had no known ortholog in the three model organisms, and were given the lowest priority.
After prioritization, Ingenuity pathway analysis (IPA) was used to create PPI networks by interfacing genes from the C. elegans-guided human EYA1 interactome with genes present within the novel deletion intervals (Supplementary Material-Gene Prioritization within Novel CNVRs for example and IPA settings). Genes (or connecting genes) present in both lists were used to condense the interconnected PPI networks into a succinct system of relationships that involved known human BOR-causing genes, human orthologous genes from the C. elegans-guided human EYA1 interactome, and genes from the novel deletion interval (Figs. 2, S6, and S7). The result was a concise PPI network for each novel deletion interval that elucidated the most likely BOR-causing genes based on known protein-protein relationships that involve EYA1 or likely interaction partners.
The results of these three methods were integrated to create a refined list of candidate disease genes for BOR that are present within these large, novel deletions (Table S9 ). All gene enrichment calculations were performed using IPA and were subjected to a Benjamini-Hochberg multiple testing correction.
Long-range PCR and break point characterization
Breakpoint characterization of EYA1-including CNVs was completed by LR-PCR using the TAKARA PCR System kit (TaKaRa LA Taq, Takara Bio, Shiga, Japan). Primer pairs covering putative break points for each deletion were designed using Primer3 (http://frodo.wi.mit.edu/). PCR products were resolved on a 1.0 % agarose gel, visualized by ethidium bromide staining, and purified using a PCR Purification Kit (Qiagen, Valencia, CA). Purified PCR products were bidirectionally Sanger sequenced according to standard protocols. Approximate genomic sequence coordinates for each deletion breakpoint were estimated based on breakpoint assessments of segMNT plots generated by Roche NimbleScan CGH software. Analysis of the sequencing results was performed using Sequencher software (Gene Codes, Ann Arbor, MI). Breakpoint regions were analyzed by RepeatMasker (http://www.repeat masker.org) for interspersed repeat and low complexity DNA sequences, and the LALIGN tool of the Swiss EMBnet (http://www.ch.embnet.org/software/LALIGN_ form.html) to compare interspersed repeat sequences.
Results aCGH analysis of BOR probands 32 of 35 BOR proband samples passed quality control requirements and were placed in the analysis pipeline using an array reuse strategy (see ''Material and methods'' and Figure S1 ). We identified approximately 5,000 high quality CNVRs (a minimum of three probes was required to call a CNV using any of the aforementioned algorithms); however, we only considered for further analysis those regions called variable by three different algorithms (see ''Materials and methods''). In total, we identified more deleted than amplified genomic content, but nonetheless identified a high number of small (\10 kb) amplifications ( Fig. S2 ; Table S1 ). Approximately 75 % of CNVRs had complete overlap with published copy number polymorphic loci in HapMap populations (Conrad et al. 2010) (Fig. S3 ; Table  S2 ) with *53 % involving at least one exon of one reviewed, provisional or hypothetical RefSeq protein-coding gene (Fig. S4 ). In total, we identified 17 diagnostic lesions, including 5 in the region including the EYA1 gene and 12 in non-EYA1 associated regions. 
Deletion type 2: large contiguous gene deletion including EYA1
Four patients had a nearly identical large genomic deletion that includes EYA1 and 9 neighboring genes (shown in Fig. 1 ; these include SULF1, SLCO5A1, PRDM14, NCOA2, TRAM1, LACTB2, XKR9, and two non-coding RNAs). Analysis of the aCGH data revealed that the distal breakpoint likely maps within a few kb of chr8: 72,587,445, hg19, whereas the proximal breakpoint likely maps within a few kb of chr8: 69,899,445, hg19, predicting a *2.7 Mb deletion. We included three of the four DNA samples in serial LR-PCR and narrowed the junction fragment to an amplicon of 2.9 kb (Table S3) . Analysis of the break point intervals using repeat masker showed that the distal break point contains 87 % masked bases while the proximal break point has 99.5 % masked bases. LALIGN analysis showed that these two long terminal repeats have [80 % sequence identity. Both the distal and proximal deletion breakpoints are flanked by the LTRERV_class I elements, with 89 % homology and situated in the same orientation (Table 2) . We used the significance testing for aberrant copy number algorithm to show that this region was concordantly aberrant across BOR probands more than would be expected by chance (p = 0.009). Thus, 4 of 32 patients contained a common genomic rearrangement likely mediated by non-allelic homologous recombination.
Non-EYA1 deletions and duplications
In addition to the multiple EYA1 deletions, we identified several novel microdeletions and amplifications in probands who did not have an EYA1 lesion. In total, 12 other BOR probands had a ''diagnostic'' lesion by aCGH (see ''Materials and methods'' and Table 1 ). In four of these probands, the novel deletions were [1 Mb and involved chromosomes 2q33.3q34 (6.9 Mb), 7p15.1p14.3 (11.8 Mb), 8q24.3 (3.1 Mb), and 11q13.3 (1.0 Mb). Other significant lesions involved the well-known autism susceptibility locus on 16p11.2 (two duplications and one deletion in three separate individuals), and the DiGeorge/ velo-cardiofacial Syndrome locus on 22q11.2 (one deletion in one patient and one duplication found in the same patient as the 11q13.3 deletion). The four remaining diagnostic lesions included a 630-Kb deletion of 7q35 involving exons 2-8 of the CNTNAP2 gene (located in the known deafness locus DFNB13, with no gene identification yet). These non-EYA1 diagnostic lesions have been summarized in Table S4 . In addition to these diagnostic lesions we found 52 rare and novel CNVRs that were of interest but \100 Kb in size (Table S4) . Available clinical data on all patients with likely pathogenic CNVs (either EYA1-or non EYA1-associated) are summarized in Table 3 .
Gene prioritization in novel CNVs
To determine which genes within the larger ([1 Mb) novel deletions are likely contributors to the BOR phenotype, we completed three separate yet complementary prioritization analyses of the genes within these intervals. The first analysis, termed ''overlap'' analysis (see ''Materials and methods''), was selected because phenotypic data are often lacking for many of the CNVs reported within clinical databases. Thus, it is possible that these CNVs may cause a phenotype similar to BOR or may involve one of the primary organ systems affected in BOR. From this analysis we identified genes that were present in a region of 'moderate overlap' across multiple clinically relevant CNVs (see ''Materials and methods'' and Figure S5 ), hypothesizing that genes within this region are more likely Fig. 1 Identification of a recurrent EYA1 deletion. Arraybased CGH results visualized in the Roche NimbleGen SignalMap genome browser generated with default segMNT algorithm settings (12,000 bp averaging). Probands (cases) are indicated above each segmentation profile. Genes (collapsed) are indicated above segmentation data; EYA1 is labeled. Genomic locations are indicated at the top of the Figure  ( to cause a human disease phenotype (Table S5 ). Our second analysis ranked genes within deletions according to the likelihood of haploinsufficiency (Huang et al. 2010) (Table  S6 ). The third analysis created and examined proteinprotein interaction networks. To guide this analysis, we utilized the C. elegans interactome and orthologous human genes to create a hypothetical EYA1 interactome (Table  S7) . We used Ingenuity pathway analysis (IPA) to create two sets of PPI networks using: (1) genes from both the C. elegans-guided human EYA1 interactome (Fig. S6) , and (2) those genes within the novel deletion intervals. Genes present in both sets of PPI networks were identified and used to intersect and condense the separate PPI networks into a succinct system of relationships that involved known BOR-causing genes, genes from the C. elegans-guided human EYA1 interactome, and genes from the novel deletion intervals (see ''Materials and methods''; Fig. S7 ). The result was a concise PPI network for each novel deletion interval ( Fig. 2 ; Table S8 ). These separate networks were then combined into one large network (see ''Materials and methods'' and Fig. 3) . Notably, this network is significantly enriched for genes involved in both morphogenesis of the metanephric bud (p = 0.001) and development of the inner ear (p = 0.001; see ''Materials and methods''). The results of these analyses also yielded a set of high quality candidate disease genes for BOR (Table 4 ; see Table S9 for a more expanded view of potential candidates). Fig. 2 Individual concise protein-protein interaction networks generated for each large, novel deletion found in the BOR cohort using a C. elegans EYA1 interactome informed IPA analysis. IPA core analysis of the human orthologs of the good C. elegans EYA1 interacting candidates produced three dominant PPI networks (BOR Interactomes 1, 2, and 3). IPA core analysis of the genes contained within the large, novel deletions often produced just one dominant network. Molecules present in both sets of PPI networks were identified and used to intersect and condense the separate PPI networks into a succinct system of relationships that involved known BOR-causing genes (EYA1, SIX1), genes from the C. elegans-guided human EYA1 interactome (BOR Interactomes), and genes from the novel deletion intervals. Genes present in the BOR-related deletion (A: Chr2 deletion, B: Chr7 deletion, C: Chr8 deletion, D: Chr11 deletion) are indicated. All network connections and molecules are labeled in orange and all identification tags and lines are in grey/ green. The ''C. elegans Best BOR Candidates'' tag refers to those molecules that were explicitly contained in the good C. elegans EYA1 interacting candidate list and not only a product of IPA network generation. EYA1 is highlighted with a green box across all pathways for orientation. 
Discussion
Here we use copy number variation analysis on a cohort of BOR cases to identify five probands (out of a total of 32) with a complete or partial EYA1 deletion, further demonstrating that EYA1 is a key player in this disorder. To identify other potential candidates, we used interactome data to perform network analysis of CNV-associated genes to identify pathways enriched in our gene dataset. Notably, in our gene sets, we identified significant enrichment for pathways involved in development of the organ systems directly affected by BOR (morphogenesis of the Fig. 3 C. elegans and CNVaided human EYA1 interactome. The smaller network shown in a is composed of molecules that are known BOR pathogenic genes, candidate BOR genes from the C. elegans EYA1 interactome, and genes (highlighted with orange symbols and red boxes) present in the four large, novel deletions found within the BOR cohort examined in this study. The larger network shown in b is a more comprehensive network that also includes genes found within other diagnostic CNVRs and variants of unknown significance (also highlighted with orange symbols and red or green boxes). EYA1 is highlighted with a green box for orientation. Dotted lines reflect indirect relationships and solid lines indicate direct relationships (color figure online) metanephric bud and development of the inner ear) and identified SHARPIN, FGF3, and the HOXA gene cluster as potential BOR candidate genes.
EYA1-associated deletions are a frequent cause of BOR
Four of the 32 unrelated BOR cases contained a common *2.7 Mbp deletion involving EYA1, with the breakpoints residing in LTR elements of the ERV1 retrovirus family. Given the frequency of this deletion (12.5 % of the total number of cases), it is likely that this rearrangement is a relatively common event leading to BOR in patients negative for EYA1 coding region and splice-site mutations by Sanger sequencing. Along these lines, Sanchez-Valle and colleagues (2010) identified the same deletion in one of three DNA samples from cases where high-resolution CGH was performed, providing additional evidence that this rearrangement is an important cause of BOR. Both retroviral elements associated with the rearrangement breakpoints are[3 kb in length and the element nearest to EYA1 is in close proximity (\5 Kb) to a second ERV1 family LTR element. In addition to the four large EYA1-associated deletions, we identified a smaller deletion that removed the last exon of EYA1, and the 3 0 UTR and polyadenylation signal. Thus, the resulting message is likely destabilized and quickly degraded. In total, 5 of 32 probands (14 %) had EYA1-associated deletions. Although we cannot rule out the possibility that additional probands might harbor regulatory mutations in the EYA1 locus, it is likely that other genes contribute to the BOR phenotype (see below). In addition, we note that we failed to identify deletions of either of the other two known BOR-causing genes, SIX1 or SIX5, in any of our probands.
SHARPIN, FGF3
, and the HOXA gene cluster are novel BOR candidate genes The genes we identified as possible candidates for causing and/or influencing the BOR phenotype are high probability candidates because they rose to the top of the three-tiered prioritization analysis and also have independent lines of evidence to support a possible role in a BOR phenotype. SHARPIN, present in the novel deletion on chromosome 8, has been shown to be a novel Eya1 binding partner in mice and plays a critical role in craniofacial development (Landgraf et al. 2010 ). Specifically, morpholino-mediated knockdown of the zebrafish ortholog of SHARPIN produces a BOR syndrome-like phenotype and shows that Sipl1 directs the development of several organs including the ears and branchial arches. Sipl1 is co-expressed with Eya1 in several organs during murine and zebrafish embryogenesis and at the molecular level, acts as cofactor for the Eya-Six complex. The phenotype in the patient 516570 carrying this large chromosome 8q24.3 deletion included cardiac defects (TOF) in addition to hearing loss, pinnae deformity (cup ear), preauricular pits and asymmetric kidneys.
The 11.8 Mbp large deletion of 7p15.1-14.3 found in the patient 2740 removes the genes of the HOXA gene cluster, which themselves are good BOR candidates since they are known to be involved in craniofacial development (VieilleGrosjean et al. 1997) . Whereas HOXA2 did not score very high compared to other members of the HOXA cluster in our prioritization analysis, it plays a critical role in development of the middle and external ear (Alasti et al. 2008; O'Gorman 2005; Tischfield et al. 2005; VieilleGrosjean et al. 1997 ) and mutation of its highly conserved homeodomain has been causally implicated in autosomal recessive bilateral microtia, mixed symmetrical severe-toprofound hearing impairment and cleft palate (Alasti et al. 2008) . Of the other HOXA family members, a homozygous mutation of HOXA1 has been reported to disrupt the inner and outer ear and cause facial, brainstem, and cardiac abnormalities (Tischfield et al. 2005) . HOXA13, which ranked high in our analysis, has been implicated in dominantly inherited hand-foot-genital syndrome (Goodman et al. 2000) . The phenotype of patient 2740 carrying the deletion of 7p15.1-14.3 included cardiac defects, brachydactyly, and hydrometrocolpos in addition to hearing loss, branchial fistulae, branchial cyst, and small hypoplastic kidneys. We believe this patient likely represents a distinctive novel contiguous gene deletion syndrome.
Within the chromosome 11 deletion, FGF3 is a strong BOR-causing and/or modifying gene candidate because its murine ortholog has been shown to be required for inner ear patterning (Gregory-Evans et al. 2007; Leger and Brand 2002; Wright and Mansour 2003; Xu et al. 1999a) , and mice harboring Fgf-3 mutations have inner ear defects (Mansour et al. 1993) . In humans, microdeletions involving this locus are associated with oto-dental syndrome, a rare but severe autosomal dominant craniofacial abnormality that includes sensorineural hearing loss (Gregory-Evans et al. 2007 ).
Lastly, the chromosome 2 deletion provides for a few potential candidates, although these candidates are not as strong as those found in the other large, novel deletions.
Known susceptibility loci likely play a role in BOR Unexpectedly, given our relatively small sample size, we observed a high incidence of variants involving known susceptibility loci, such as the autism susceptibility locus on 16p11.2 (two duplications, one deletion) and the DiGeorge/velo-cardiofacial syndrome locus on 22q11.2 (one duplication). Deletions and duplications of 16p11.2 have been associated with numerous phenotypes, including autism, schizophrenia, seizures, developmental delay, and obesity. Amongst neuropsychiatric disorders, deletions may be more commonly associated with autism and duplications with schizophrenia (McCarthy et al. 2009 ), though these relationships are not exclusive. The copy number variation at this locus could be either inherited or de novo, and the phenotype can vary across family members to the extent that not all individuals with the deletion or duplication have an identifiable phenotype. Several additional phenotypes have been associated with copy number variation at 16p11.2 including ones that involve the genitourinary organ system including Mullerian aplasia (Nik-Zainal et al. 2011 ), hypospadias (Tannour-Louet et al. 2010 , and congenital anomalies of the kidney and urinary tract (CAKUT) (Sampson et al. 2010) . How or whether these variations influence the BOR phenotype is unclear, yet our results add further support to the heterogeneity in phenotype related to deletions/duplications at 16p11.2. Duplications of 22q11.2 represent the predicted reciprocal rearrangements to 22q11.2 deletions, and contain *50 verified genes, including TBX1. They are most often inherited from an apparently unaffected parent, and the associated phenotype is variable, ranging from multiple defects to mild learning difficulties. Duplications of this locus share features with the more common deletion and include genitourinary abnormalities (Portnoi 2009 ). The incidence of urogenital abnormalities in the classic 22q deletion syndrome is well documented and can include renal agenesis, hydronephrosis, multicystic/dysplastic kidneys, duplicated kidney, horseshoe kidney, absent uterus, hypospadias, inguinal hernia, and cryptorchidism (McDonald-McGinn et al. 2005) . We observed one 22q deletion (in patient 2330) and one 22q duplication (in patient 21790). The first patient's phenotype also included Mondini dysplasia, making ATP6V1E1, SLC25A1, and SLC25A18 interesting candidates, and the patient with the 22q duplication also carried the chromosome 11 deletion (including FGF3), raising the possibility of a novel CNV-CNV interaction. Summary BOR syndrome is a very common form of syndromic hearing loss that additionally includes branchial arch and renal abnormalities. The majority of cases are caused by mutations in EYA1 (*40 % of BOR cases: 80 % point mutations and small indels, 20 % large deletions) although SIX1 and SIX5 also make small contributions to the BOR phenotype. In this study, we identified 17 diagnostic CNV lesions in 32 BOR probands, including 5 in the region containing EYA1 and 12 in non-EYA1 associated regions. Deletion of all or part of EYA1 in 14 % of our patients further supports the strong association of EYA1 with BOR.
Using a novel disease-gene prioritization strategy (integration of three methods) that includes pathway analysis of genes in the non-EYA1 large, novel deleted interval regions, we have identified a set of strong candidate genes associated with the pathogenesis of BOR syndrome including SHARPIN (Sipl1), FGF3, and the HOXA cluster.
Consistent with this hypothesis, in each case, mutation or knockdown of each of these genes has been shown to cause phenotypes similar to BOR in either humans or other model organisms (see above).
